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OAB incur lower total costs for OAB management when
the cost of incontinence pads are considered.
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Basiliximab, daclizumab, and OKT3 are potent immuno-
suppressive induction agents used in kidney transplanta-
tion. All four agents have demonstrated statistically sig-
nificant reductions in the incidence of acute rejection
compared to standard therapy. However, the cost-effec-
tiveness of these induction agents has not been studied in
a uniform context or explored beyond a 1-year period
following transplantation. OBJECTIVE: The purpose of
this study is to estimate cost-effectiveness of basiliximab,
daclizumab, and OKT3 compared to standard therapy
over a 5-year period post transplantation using a societal
perspective. METHODS: A Markov model was con-
structed using four states (eventfree, rejection/graft sur-
vival, graft failure/dialysis, death) to reflect the different
clinical and economic states of transplant patients. The
costs examined included initial hospitalization cost, acute
rejection treatment cost, cost of graft failure and subse-
quent dialysis, cost of maintaining functional graft, and
drug cost for induction agents. The transition probabili-
ties and utilities were obtained from the randomized tri-
als and other literature. Costs were obtained from the US
Renal Data System Annual Report, the University Health-
System Consortium Pharmacy Database, the Red Book,
and literature. RESULTS: Average costs for the first year
post transplantation ranged from $58,052 to $78,153
and five-year total costs were estimated to be $154,806
(basiliximab), $155,712 (daclizumab), $181,113 (OKT3),
and $166,124 (standard therapy). Daclizumab ($48,665/
QALY) and basiliximab ($51,182/QALY) were more
cost-effective than standard therapy ($56,646/QALY) or
OKT3 ($60,391/QALY). CONCLUSION: Preliminary
results suggest that daclizumab and basiliximab are cost-
effective induction agents compared to standard therapy
when considered over a 5-year period following trans-
plantation. Extensive sensitivity analysis is planned to
test the robustness of this finding.
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The prevalence of peritoneal dialysis (PD) in the USA is
12%. PD is less costly and as effective as hemodialysis
(HD) for most patients. OBJECTIVE: To project savings
from a shift in modality distribution (MD) to home-
based therapies. METHOD: We developed a decision
model to assess the cost impact of changes in MD, mo-
dality cost (MC) or numbers of patients. IPD was ex-
cluded. Using 1999 USRDS data, we calculated MC and
applied patient numbers and MD. We previously sur-
veyed US nephrologists who opined optimal MD to max-
imize survival was: hospital HD 9.2%; community full-
care HD 33.9%; community self-care HD 13.8%; home
HD 12.1%; CAPD 17.5%; APD 14.3%; and IPD 1.5%.
To maximize cost-effectiveness the percentages changed
to 4.2, 24.9, 15.5, 16.5, 26.7, 12.4, and 1.0% respec-
tively. The estimated total dialysis spend, excluding epoi-
etin and non-ambulance transportation, was generated
and compared to the total cost using the “optimized”
MD. RESULTS: A total dialysis spend of $11.25 billion
was estimated using MD from the USRDS. The total sav-
ings and additional patients who could be treated at the
MD opined for maximum survival was $750 million
(6.7%) and 15,745, respectively; for maximum cost sav-
ings, $1.06 billion (9.5%) and 22,977. Survey limita-
tions, costing assumptions and modeling suggest caution
that the potential savings identified may or may not be
completely achievable. CONCLUSION: Effecting a change
in MD in accordance with what US nephrologists re-
ported to be acceptable could lead to substantial Medi-
care savings. Strategies to increase utilization of home
and self care therapies, which might include earlier refer-
ral and empowerment of patient choice, should be con-
sidered.
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OBJECTIVE: The objective of this study was to assess
the feasibility and usefulness of administering a quality of
life questionnaire within routine clinical practice with re-
nal patients. METHODS: This was a national 5 centre
study administering a disease-specific questionnaire, the
Renal Quality of Life Profile (RQLP). The RQLP was ad-
ministered by nurses to patients in addition to some de-
mographic and open-ended questions. Nurses reviewed
the completed questionnaire to identify potential areas
requiring discussion and contacted the patient to discuss.
RESULTS: The RQLP was administered to 140 patients:
24 predialysis, 12 home haemodialysis, 25 satellite hae-
modialysis, 21 hospital haemodialysis, 32 CAPD, and 26
transplant. 44% completed the questionnaire in the wait-
ing room, 22% in the consulting room, and 34% on dial-
ysis or at home. During questionnaire review, nurses felt
